Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPS NASDAQ:COLL NASDAQ:TARA NASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCompass Pathways$9.76+4.7%$6.83$2.25▼$10.21$1.20B2.395.87 million shs2.43 million shsCOLLCollegium Pharmaceutical$36.51+3.4%$35.46$26.72▼$50.79$1.14B0.76484,688 shs900,916 shsTARAProtara Therapeutics$5.66+4.6%$5.37$2.77▼$7.82$297.88M1.53620,802 shs577,040 shsURGNUrogen Pharma$26.25+10.2%$20.48$3.42▼$30.00$1.16B1.58825,333 shs2.83 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCompass Pathways+4.72%+16.47%+69.74%+70.93%+168.13%COLLCollegium Pharmaceutical+3.25%+8.15%+12.03%-22.19%+35.07%TARAProtara Therapeutics+4.62%+9.48%+11.64%-12.92%+67.95%URGNUrogen Pharma+10.16%+12.47%+41.05%+27.92%+170.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCompass Pathways$9.76+4.7%$6.83$2.25▼$10.21$1.20B2.395.87 million shs2.43 million shsCOLLCollegium Pharmaceutical$36.51+3.4%$35.46$26.72▼$50.79$1.14B0.76484,688 shs900,916 shsTARAProtara Therapeutics$5.66+4.6%$5.37$2.77▼$7.82$297.88M1.53620,802 shs577,040 shsURGNUrogen Pharma$26.25+10.2%$20.48$3.42▼$30.00$1.16B1.58825,333 shs2.83 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCompass Pathways+4.72%+16.47%+69.74%+70.93%+168.13%COLLCollegium Pharmaceutical+3.25%+8.15%+12.03%-22.19%+35.07%TARAProtara Therapeutics+4.62%+9.48%+11.64%-12.92%+67.95%URGNUrogen Pharma+10.16%+12.47%+41.05%+27.92%+170.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPSCompass Pathways 2.91Moderate Buy$20.45109.58% UpsideCOLLCollegium Pharmaceutical 2.57Moderate Buy$53.4046.26% UpsideTARAProtara Therapeutics 2.83Moderate Buy$24.75337.28% UpsideURGNUrogen Pharma 2.78Moderate Buy$34.1330.00% UpsideCurrent Analyst Ratings BreakdownLatest TARA, CMPS, URGN, and COLL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026CMPSCompass Pathways Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/3/2026CMPSCompass Pathways Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$18.004/29/2026TARAProtara Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$23.00 ➝ $27.004/28/2026CMPSCompass Pathways HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.004/24/2026CMPSCompass Pathways UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$17.004/24/2026CMPSCompass Pathways B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$17.004/24/2026URGNUrogen Pharma Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026TARAProtara Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CMPSCompass Pathways Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026URGNUrogen Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CMPSCompass Pathways BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.00(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPSCompass PathwaysN/AN/AN/AN/A($0.55) per shareN/ACOLLCollegium Pharmaceutical$780.57M1.52$15.74 per share2.32$9.54 per share3.83TARAProtara TherapeuticsN/AN/AN/AN/A$3.80 per shareN/AURGNUrogen Pharma$109.79M11.65N/AN/A($2.25) per share-11.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPSCompass Pathways-$287.86M-$3.09N/AN/AN/AN/A-192.95%-61.31%5/13/2026 (Confirmed)COLLCollegium Pharmaceutical$62.87M$1.7121.356.88N/A8.05%98.65%15.86%5/7/2026 (Estimated)TARAProtara Therapeutics-$57.44M-$1.32N/AN/AN/AN/A-36.38%-33.81%5/14/2026 (Estimated)URGNUrogen Pharma-$153.49M-$3.20N/A33.23N/A-139.81%N/A-72.93%N/ALatest TARA, CMPS, URGN, and COLL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026TARAProtara Therapeutics-$0.36N/AN/AN/AN/AN/A5/7/2026Q1 2026CMPSCompass Pathways-$0.45N/AN/AN/AN/AN/A5/7/2026Q1 2026COLLCollegium Pharmaceutical$1.52N/AN/AN/A$184.47 millionN/A5/6/2026Q1 2026URGNUrogen Pharma-$0.4824-$0.47+$0.0124-$0.47$44.83 million$50.96 million3/24/2026Q4 2025CMPSCompass Pathways-$0.41-$1.00-$0.59-$1.00N/AN/A3/10/2026Q4 2025TARAProtara Therapeutics-$0.34-$0.37-$0.03-$0.37N/AN/A3/2/2026Q4 2025URGNUrogen Pharma-$0.66-$0.54+$0.12-$0.54$39.92 million$37.84 million2/26/2026Q4 2025COLLCollegium Pharmaceutical$2.20$2.04-$0.16$0.46$206.36 million$205.45 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCMPSCompass PathwaysN/AN/AN/AN/AN/ACOLLCollegium PharmaceuticalN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPSCompass Pathways0.550.770.77COLLCollegium Pharmaceutical2.591.571.48TARAProtara TherapeuticsN/A14.5814.58URGNUrogen PharmaN/A4.013.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPSCompass Pathways46.19%COLLCollegium PharmaceuticalN/ATARAProtara Therapeutics38.13%URGNUrogen Pharma91.29%Insider OwnershipCompanyInsider OwnershipCMPSCompass Pathways2.82%COLLCollegium Pharmaceutical1.85%TARAProtara Therapeutics8.40%URGNUrogen Pharma4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPSCompass Pathways120128.92 million125.29 millionOptionableCOLLCollegium Pharmaceutical21032.41 million31.81 millionOptionableTARAProtara Therapeutics3055.06 million50.44 millionOptionableURGNUrogen Pharma20048.72 million46.43 millionOptionableTARA, CMPS, URGN, and COLL HeadlinesRecent News About These CompaniesUroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call TranscriptMay 6 at 6:10 PM | seekingalpha.comUrogen Pharma (NASDAQ:URGN) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSMay 6 at 3:27 PM | marketbeat.comUrogen Pharma (NASDAQ:URGN) Trading Up 14% on Better-Than-Expected EarningsMay 6 at 2:33 PM | marketbeat.comUrogen Pharma (URGN) Reports Q1 Loss, Beats Revenue EstimatesMay 6 at 10:30 AM | zacks.comUroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and HighlightsMay 6 at 8:00 AM | globenewswire.comUrogen Pharma (URGN) Projected to Post Earnings on WednesdayMay 2, 2026 | americanbankingnews.comUrogen Pharma (URGN) Projected to Post Quarterly Earnings on WednesdayMay 2, 2026 | marketbeat.comUroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026April 29, 2026 | globenewswire.comHC Wainwright Predicts Urogen Pharma Q1 EarningsApril 27, 2026 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Rating Increased to Strong-Buy at Jefferies Financial GroupApril 25, 2026 | marketbeat.comHC Wainwright Predicts Urogen Pharma Q3 EarningsApril 24, 2026 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Trading Up 9% - Should You Buy?April 20, 2026 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Moderate Buy" by AnalystsApril 20, 2026 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Trading Down 4.5% - What's Next?April 13, 2026 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Shares Gap Up - Time to Buy?April 10, 2026 | marketbeat.comJefferies Financial Group Initiates Coverage on Urogen Pharma (NASDAQ:URGN)April 10, 2026 | marketbeat.comUroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial CancerApril 8, 2026 | globenewswire.comWhy The UroGen Pharma (URGN) Investment Story Is Shifting As Analysts Hold Fair Value SteadyApril 4, 2026 | finance.yahoo.comStocks showing rising market leadership: UroGen Pharma earns 82 RS ratingApril 2, 2026 | msn.comJournal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURIMarch 30, 2026 | globenewswire.comHow UroGen Pharma (URGN) Narrative Is Evolving Around Fair Value Risks And OpportunitiesMarch 20, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 2026This 4/20, Wall Street Is Betting on More Than MarijuanaBy Jeffrey Neal Johnson | April 20, 2026These 3 Psychedelic Stocks Activated After Trump's Executive OrderBy Nathan Reiff | April 27, 2026TARA, CMPS, URGN, and COLL Company DescriptionsCompass Pathways NASDAQ:CMPS$9.76 +0.44 (+4.72%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$9.76 0.00 (-0.05%) As of 05/6/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Collegium Pharmaceutical NASDAQ:COLL$36.51 +1.19 (+3.37%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$36.52 +0.01 (+0.03%) As of 05/6/2026 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Protara Therapeutics NASDAQ:TARA$5.66 +0.25 (+4.62%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$5.62 -0.04 (-0.80%) As of 05/6/2026 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.Urogen Pharma NASDAQ:URGN$26.25 +2.42 (+10.16%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$25.90 -0.35 (-1.33%) As of 05/6/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Years in the Making, AMD’s Upside Movement Has Just Begun Capital One’s Big Bet Faces Rising Credit Risk Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
